Remove 2026 Remove Drug Pricing Remove Hospitals
article thumbnail

STAT+: Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more

STAT

government agency has threatened Johnson & Johnson with sanctions if the company proceeds with plans to alter payment methods for some hospitals that participate in a federal drug discount program , STAT reports. We hope you have a wonderful day, and please do keep in touch. … A U.S.

Hospitals 286
article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). Active Moiety and Single Source Qualifying Drugs (Section 30.1)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

Timely implementation is particularly critical for beneficiaries requiring immediate mental health or substance use treatment, where delays can lead to worsening health outcomes, increased hospitalization rates, and preventable mortality. Issue Brief: Improving Prescription Drug Price and Cost Transparency. 2024.30.2.206.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.